Trial Profile
An Efficacy and Tolerability Study of MK0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 0533 (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 05 Oct 2008 Actual start date Oct 2007 to Jun 2006 as reported by CT.gov
- 05 Oct 2008 Planned end date added (Sep 2007) as reported by CT.gov
- 30 Oct 2007 New trial record.